[go: up one dir, main page]

WO2012129145A8 - Nsclc combination therapy - Google Patents

Nsclc combination therapy Download PDF

Info

Publication number
WO2012129145A8
WO2012129145A8 PCT/US2012/029598 US2012029598W WO2012129145A8 WO 2012129145 A8 WO2012129145 A8 WO 2012129145A8 US 2012029598 W US2012029598 W US 2012029598W WO 2012129145 A8 WO2012129145 A8 WO 2012129145A8
Authority
WO
WIPO (PCT)
Prior art keywords
nsclc
combination therapy
nsclc combination
osi
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/029598
Other languages
French (fr)
Other versions
WO2012129145A1 (en
Inventor
Stuart Thomson
Eric N. Brown
Andrew Chau
Maryland Franklin
Kenneth K. Iwata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSI Pharmaceuticals LLC filed Critical OSI Pharmaceuticals LLC
Publication of WO2012129145A1 publication Critical patent/WO2012129145A1/en
Publication of WO2012129145A8 publication Critical patent/WO2012129145A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treating NSCLC comprising in some aspects administering OSI-906 and an EGFR inhibitor to a patient having NSCLC having an activating EGFR mutation, as disclosed herein.
PCT/US2012/029598 2011-03-18 2012-03-19 Nscle combination therapy Ceased WO2012129145A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161454059P 2011-03-18 2011-03-18
US61/454,059 2011-03-18

Publications (2)

Publication Number Publication Date
WO2012129145A1 WO2012129145A1 (en) 2012-09-27
WO2012129145A8 true WO2012129145A8 (en) 2013-04-11

Family

ID=45894694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/029598 Ceased WO2012129145A1 (en) 2011-03-18 2012-03-19 Nscle combination therapy

Country Status (1)

Country Link
WO (1) WO2012129145A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305682A1 (en) 2004-04-02 2011-04-06 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
EP2421837A1 (en) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69222637T2 (en) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int UP TO MONO AND BICYCLIC ARYL AND HETEROARYL DERIVATIVES WITH INHIBITING EFFECT ON EGF AND / OR PDGF RECEPTOR TYROSINKINASE
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CA2148931A1 (en) 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
EP0682027B1 (en) 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidine derivatives with antiproliferative action
ES2332984T3 (en) 1995-03-30 2010-02-16 Pfizer Products Inc. DERIVATIVES OF QUINAZOLINAS.
ATE195123T1 (en) 1995-04-03 2000-08-15 Novartis Erfind Verwalt Gmbh PYRAZOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
ES2172670T3 (en) 1995-07-06 2002-10-01 Novartis Ag PIRROLPIRIMIDINAS AND PROCEDURES FOR THEIR PREPARATION.
DK9500262U4 (en) 1995-07-07 1996-10-07 Bonus Energy As Bottom frame for wind turbine housing and wind turbine comprising the same
AR004010A1 (en) 1995-10-11 1998-09-30 Glaxo Group Ltd HETERO CYCLIC COMPOUNDS
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
PT888349E (en) 1996-01-23 2002-10-31 Novartis Ag PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION
JP3406763B2 (en) 1996-01-30 2003-05-12 東レ・ダウコーニング・シリコーン株式会社 Silicone rubber composition
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19608588A1 (en) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation
DE19629652A1 (en) 1996-03-06 1998-01-29 Thomae Gmbh Dr K 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation
NZ331804A (en) 1996-03-15 2000-04-28 Novartis Ag N-7-heterocyclyl pyrrolo[2,3-d]pyridines and their use
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
BR9709959A (en) 1996-06-24 2000-05-09 Pfizer Tricyclic derivatives of substituted phenylamino for the treatment of hyperproliferative diseases
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
CA2260058A1 (en) 1996-07-13 1998-01-22 Kathryn Jane Smith Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
PT912559E (en) 1996-07-13 2003-03-31 Glaxo Group Ltd HETEROCYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS TYROSINE KINASE
JP4242928B2 (en) 1996-08-23 2009-03-25 ノバルティス アクチエンゲゼルシャフト Substituted pyrrolopyrimidine and process for producing the same
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT
WO1998014449A1 (en) 1996-10-02 1998-04-09 Novartis Ag Fused pyrazole derivatives and processes for their preparation
US6251911B1 (en) 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
ATE391719T1 (en) 1997-02-05 2008-04-15 Warner Lambert Co PYRIDO (2,3-D) PYRIMIDINES AND 4-AMINO-PRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION
US6329375B1 (en) 1997-08-05 2001-12-11 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
HK1040720A1 (en) 1998-05-15 2002-06-21 伊姆克罗尼系统公司 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
AU782994C (en) 1999-05-14 2006-08-24 Imclone Llc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
HUP0203162A3 (en) 1999-08-12 2006-07-28 Wyeth Holdings Corp Madison Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
IL151781A0 (en) 2000-03-16 2003-04-10 Genetica Inc Methods and compositions for rna interference
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
AU2002239486A1 (en) 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
WO2002055106A2 (en) 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
CA2449166A1 (en) 2001-05-08 2002-11-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-egfr antibodies and anti-hormonal agents
AR035885A1 (en) 2001-05-14 2004-07-21 Novartis Ag DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
US20050215530A1 (en) 2002-04-16 2005-09-29 Ryan Anderson J Combination therapy for the treatment of cancer
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
ES2741546T3 (en) 2004-03-31 2020-02-11 Massachusetts Gen Hospital Method to determine the response of cancer to treatments directed at the epidermal growth factor receptor
EP2305682A1 (en) 2004-04-02 2011-04-06 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor

Also Published As

Publication number Publication date
WO2012129145A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
WO2012062925A3 (en) Compounds and methods for treating pain
MX363243B (en) Compositions and methods for treating cancer.
MX2011008221A (en) Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor.
WO2013059396A3 (en) Treatment of cancer with tor kinase inhibitors
WO2011130389A3 (en) System and method for microablation of tissue
WO2013028262A3 (en) Systems and methods for stimulating cellular function in tissue
HK1213889A1 (en) Glutaminase inhibitors and method of use
WO2013076586A9 (en) Systems, methods, and computer program products for guiding the selection of therapeutic treatment regiments
SG195110A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
WO2013019945A3 (en) Method for selection of chemotherapeutic agents for adenocarcinoma cancer
MX2014010940A (en) The use of antithrombin in the treatment of pre-eclampsia.
MX2014000150A (en) Systems, methods, and formulations for treating cancer.
BR112014012495A2 (en) in vitro method, kit, egfr inhibitor and method of treating cancer affected patients
WO2014062878A3 (en) Treatment of prostate cancer with tor kinase inhibitors
HK1200534A1 (en) Cd8+t-cell subsets as markers for prediction of delayed fracture healing
PH12013501163A1 (en) Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer
WO2012016229A3 (en) Oxytocin treatment to improve memory and modify blood glucose
MX340536B (en) Egfr targeted therapy.
WO2012037008A3 (en) Therapy for mll-rearranged leukemia
HK1201204A1 (en) Methods for treating a stroke-related sensorimotor impairment using aminopyridines
WO2012129145A8 (en) Nsclc combination therapy
WO2014026013A3 (en) Methods for maintaining or improving health, well-being and/or a physiological function in a subject
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX351765B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12711095

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12711095

Country of ref document: EP

Kind code of ref document: A1